Can-Fite BioPharma Ltd. [AMEX: CANF] closed the trading session at $2.92 on 03/16/21. The day’s price range saw the stock hit a low of $2.85, while the highest price level was $4.39. The company report on March 16, 2021 that Can-Fite Signs $42.7 Million Out-Licensing Deal with Ewopharma.
Swiss Ewopharma to market Piclidenoson and Namodenoson in Central Eastern Europe (CEE).
$2.25 million upfront payment with an additional $40.45 million for regulatory & sales milestones and 17.5% royalties are included.
The stocks have a year to date performance of 64.04 percent and weekly performance of 51.30 percent. The stock has been moved at 59.56 percent over the last six months. The stock has performed 8.15 percent around the most recent 30 days and changed 48.22 percent over the most recent 3-months.
If compared to the average trading volume of 1.06M shares, CANF reached to a volume of 173370558 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here’s what leading stock market gurus have to say about Can-Fite BioPharma Ltd. [CANF]:
Maxim Group have made an estimate for Can-Fite BioPharma Ltd. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on August 11, 2017. The new note on the price target was released on October 19, 2016, representing the official price target for Can-Fite BioPharma Ltd. stock. Previously, the target price had yet another raise to $6, while Rodman & Renshaw analysts kept a Buy rating on CANF stock. On November 30, 2015, analysts increased their price target for CANF shares from 4 to 6.
The Average True Range (ATR) for Can-Fite BioPharma Ltd. is set at 0.37, with the Price to Sales ratio for CANF stock in the period of the last 12 months amounting to 55.91. The Price to Book ratio for the last quarter was 4.63.
CANF stock trade performance evaluation
Can-Fite BioPharma Ltd. [CANF] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 51.30. With this latest performance, CANF shares gained by 8.15% in over the last four-week period, additionally plugging by 59.56% over the last 6 months – not to mention a rise of 102.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for CANF stock in for the last two-week period is set at 71.90, with the RSI for the last a single of trading hit 79.27, and the three-weeks RSI is set at 67.73 for Can-Fite BioPharma Ltd. [CANF]. The present Moving Average for the last 50 days of trading for this stock 2.10, while it was recorded at 2.18 for the last single week of trading, and 1.98 for the last 200 days.
Can-Fite BioPharma Ltd. [CANF]: An insightful look at the core fundamentals
Operating Margin for any stock indicates how profitable investing would be, and Can-Fite BioPharma Ltd. [CANF] shares currently have an operating margin of -590.70. Can-Fite BioPharma Ltd.’s Net Margin is presently recorded at -471.80.
Return on Total Capital for CANF is now -587.68, given the latest momentum, and Return on Invested Capital for the company is -473.43. Return on Equity for this stock declined to -477.89, with Return on Assets sitting at -117.89. When it comes to the capital structure of this company, Can-Fite BioPharma Ltd. [CANF] has a Total Debt to Total Equity ratio set at 8.55. Additionally, CANF Total Debt to Total Capital is recorded at 7.88, with Total Debt to Total Assets ending up at 0.92. Long-Term Debt to Equity for the company is recorded at 4.45, with the Long-Term Debt to Total Capital now at 4.10.
Reflecting on the efficiency of the workforce at the company, Can-Fite BioPharma Ltd. [CANF] managed to generate an average of -$4,269,818 per employee. Receivables Turnover for the company is 71.84 with a Total Asset Turnover recorded at a value of 0.25.
Earnings per share (EPS) analysis for Can-Fite BioPharma Ltd. [CANF] stock
With the latest financial reports released by the company, Can-Fite BioPharma Ltd. posted -0.9/share EPS, while the average EPS was predicted by analysts to be reported at -0.66/share. When compared, the two values demonstrate that the company fail the estimates by a Surprise Factor of -36.40%. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for CANF.
Can-Fite BioPharma Ltd. [CANF]: Insider Ownership positions
There are presently around $1 million, or 6.52% of CANF stock, in the hands of institutional investors. The top three institutional holders of CANF stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 118,894, which is approximately 812.674% of the company’s market cap and around 1.19% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 74,052 shares of the stock with an approximate value of $0.22 million in CANF stocks shares; and MORGAN STANLEY, currently with $52000.0 in CANF stock with ownership of nearly 257.597% of the company’s market capitalization.
Positions in Can-Fite BioPharma Ltd. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 4 institutional holders increased their position in Can-Fite BioPharma Ltd. [AMEX:CANF] by around 194,406 shares. Additionally, 4 investors decreased positions by around 41,846 shares, while 3 investors held positions by with 7,073 shares. The mentioned changes placed institutional holdings at 243,325 shares, according to the latest SEC report filing. CANF stock had 1 new institutional investments in for a total of 15,323 shares, while 4 institutional investors sold positions of 41,846 shares during the same period.